Iterum Therapeutics plc
Iterum Therapeutics plc is a biopharmaceutical company focused on developing and commercializing ORLYNVAH™ (sulopenem etzadroxil and probenecid), an oral antibiotic for uncomplicated urinary tract infections in adult women with limited or no alternative oral treatment options. After receiving FDA approval in October 2024, the company launched ORLYNVAH in the U.S. in August 2025 and is now building a commercial organization around sales, distribution, and supply chain execution.
Tilikausi 2024 · muutos edellisvuodesta
Kehitys 2019–2024
Liiketoiminta
Osuus liikevaihdostaORLYNVAH™ is the company's approved oral antibiotic product sold in the U.S. for uUTI.
Sales, marketing, logistics, channel management, and medical affairs support outsourced to EVERSANA.
Contract manufacturing and supply of ORLYNVAH materials through ACS Dobfar and related partners.
Sulopenem-related research and development for potential future indications and products.
Asiakkaat
The primary customers are U.S. prescribers and patients in the uncomplicated UTI market, with sales driven through high-volume antibiotic prescribers and the pharmacy/channel system. The company also depends on third-party service providers for distribution, customer service, reimbursement support, and pharmacovigilance, which are essential to getting the product to end users and maintaining compliance.
Patients using ORLYNVAH when limited or no alternative oral antibacterial options are available.
Physicians and other clinicians targeted for adoption because they drive prescribing volume.
Commercial and public payers that affect formulary access, pricing, rebates, and net revenue.
Wholesalers, pharmacies, and fulfillment partners that handle inventory and dispensing.
EVERSANA and other vendors that manage commercialization, logistics, and compliance functions.
Strategia
The company's near-term strategy is to establish ORLYNVAH in the U.S. market through a focused launch, outsourced commercialization, and a limited geographic sales approach. Longer term, Iterum is trying to expand the sulopenem franchise by pursuing additional indications and potentially adding new product candidates or in-licensed assets.
The company now needs product uptake to convert its first approved asset into sustainable revenue.
Reimbursement, distribution, and patient access will determine whether the launch can scale beyond early adoption.
Additional indications could broaden the addressable market and reduce reliance on a single product.
A new commercial product requires reliable manufacturing, inventory, and quality control to avoid launch disruption.
Maantiede
Iterum's business is currently centered in the United States, where ORLYNVAH was launched in August 2025 and where the company books sales. The company also relies on international partners for manufacturing and supply, including ACS Dobfar in Europe, while its corporate structure includes non-U.S. subsidiaries used for commercialization and supply arrangements.
Riskit
Iterum remains a high-risk commercial-stage biotech with a limited operating history, a single marketed product, and substantial dependence on third parties. The company also faces going-concern risk, launch execution risk, reimbursement and pricing pressure, and regulatory/compliance exposure tied to pharmacovigilance, government pricing, and data handling.
- Going concern and financing riskVaikutus: KriittinenTodennäköisyys: Korkea
The company has incurred significant losses and has limited product revenue, so it may need additional capital to fund commercialization and development.
Kohdistuu: Corporate liquidity and operating continuity
- Commercial launch execution riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
ORLYNVAH is newly launched and sales depend on prescriber uptake, access, and field execution in a competitive antibiotic market.
Kohdistuu: Revenue ramp and market penetration
- Third-party dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
EVERSANA, ACS Dobfar, and other vendors handle key commercialization and supply functions outside direct control.
Kohdistuu - License and IP dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
The Pfizer license is central to sulopenem rights and includes diligence, milestone, and royalty obligations.
Kohdistuu: Core product rights and economics
- Government pricing and rebate complianceVaikutus: KorkeaTodennäköisyys: Matala
Errors in mandated pricing calculations or reporting could affect rebate liabilities and create False Claims Act exposure.
Kohdistuu: Net revenue and regulatory liability
- Cybersecurity and privacyVaikutus: KeskitasoTodennäköisyys: Kohtalainen
The company handles patient, commercial, and safety data, and breaches could disrupt operations or trigger legal claims.
Kohdistuu
Kirjanpito
Harkinnanvaraiset erätORLYNVAH launch requires estimating rebates, chargebacks, discounts, and returns, which directly affects reported revenue.
Vaikutus: Can materially change gross-to-net deductions and quarterly revenue
Outstanding derivative instruments are revalued each quarter under U.S. GAAP, creating non-operating gains or losses.
Vaikutus: Adds volatility below operating income and affects balance sheet liabilities
Sustained losses make realization of tax assets uncertain, requiring judgment on recoverability.
Vaikutus: Can materially affect tax expense and equity
Management must evaluate whether available cash and expected funding are sufficient to continue operations.
Vaikutus: Affects disclosure risk and investor assessment of financing needs
Third-party calculations and government program reporting feed discount and rebate liabilities.
Vaikutus: Can affect net sales, liabilities, and compliance exposure
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Spero Therapeutics, Inc.
SPRO · Pharmaceutical Preparations
Outlook Therapeutics, Inc.
OTLK · Biological Products, (No Diagnostic Substances)
United Therapeutics Corporation
UTHR · Pharmaceutical Preparations
United Therapeutics is a U.S.-based biopharmaceutical company focused on therapies for pulmonary arterial hypertension and other serious rare diseases, along with organ manufacturing technologies.
Larimar Therapeutics, Inc.
LRMR · Pharmaceutical Preparations
Actinium Pharmaceuticals, Inc.
ATNM · Pharmaceutical Preparations
Spyre Therapeutics, Inc.
SYRE · Pharmaceutical Preparations
Spyre Therapeutics is a U.S.-based clinical-stage biotechnology company focused on developing long-acting antibody therapies for inflammatory bowel disease and rheumatic diseases.
Päivitetty: 24.9.2026